Status:
ENROLLING_BY_INVITATION
Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1
Lead Sponsor:
Ann & Robert H Lurie Children's Hospital of Chicago
Collaborating Sponsors:
National Institute of Neurological Disorders and Stroke (NINDS)
Children's Hospital Medical Center, Cincinnati
Conditions:
Neurofibromatosis 1
NF1
Eligibility:
All Genders
Brief Summary
The purpose of this study is to identify tumor biomarkers in individuals with Neurofibromatosis type 1 (NF1). Biomarkers are signals that the investigator can measure that tell us about a process such...
Detailed Description
Neurofibromatosis type 1 (NF1) is a common inherited human disorder, with a frequency of approximately 1:2500 worldwide. A hallmark of NF1 is development of plexiform neurofibromas (PNFs) in 30 to 50%...
Eligibility Criteria
Inclusion
- 1\. Individuals with known diagnosis of neurofibromatosis type 1 (NF1)
Exclusion
- Patient does not meet NF1 diagnostic criteria
- Mosaic NF1 individuals
- Pregnant at Screening
- Patients who do not have the ability/capacity to undergo the informed consent process OR whose parent/legal guardian is unable to undergo the informed consent process.
Key Trial Info
Start Date :
March 4 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05238909
Start Date
March 4 2022
End Date
June 1 2027
Last Update
September 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611